IOVA Iovance Biotherapeutics Inc
Price (delayed)
$3.54
Market cap
$1.16B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.28
Enterprise value
$1.1B
Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy
Highlights
The company's gross margin has surged by 174% QoQ and by 103% YoY
IOVA's revenue has soared by 81% QoQ
IOVA's equity is up by 22% year-on-year but it is down by 8% since the previous quarter
The company's quick ratio fell by 16% QoQ but it rose by 4.1% YoY
Key stats
What are the main financial stats of IOVA
Market
Valuations
Earnings
Shares outstanding
327.88M
Market cap
$1.16B
Enterprise value
$1.1B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.52
Price to sales (P/S)
6.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.69
Revenue
$164.07M
Gross profit
$40.08M
Operating income
-$395.28M
Net income
-$372.18M
EBIT
-$375.01M
EBITDA
-$331.4M
Free cash flow
-$364.05M
Per share
Balance sheet
Liquidity
EPS
-$1.28
EPS diluted
-$1.28
Free cash flow per share
-$1.26
Book value per share
$2.33
Revenue per share
$0.57
TBVPS
$2.17
Total assets
$910.43M
Total liabilities
$200.02M
Debt
$58.26M
Equity
$710.41M
Working capital
$334.68M
Debt to equity
0.08
Current ratio
3.74
Quick ratio
3.27
Net debt/EBITDA
0.19
Margins
Efficiency
Dividend
EBITDA margin
-202%
Gross margin
24.4%
Net margin
-226.8%
Operating margin
-240.9%
Return on assets
-39.9%
Return on equity
-50.8%
Return on invested capital
-84.5%
Return on capital employed
-47.6%
Return on sales
-228.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IOVA stock price
How has the Iovance Biotherapeutics stock price performed over time
Intraday
8.92%
1 week
2.91%
1 month
-16.41%
1 year
-74.29%
YTD
-52.16%
QTD
6.31%
Financial performance
How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$164.07M
Gross profit
$40.08M
Operating income
-$395.28M
Net income
-$372.18M
Gross margin
24.4%
Net margin
-226.8%
The company's gross margin has surged by 174% QoQ and by 103% YoY
Iovance Biotherapeutics's net margin has soared by 99% YoY and by 50% from the previous quarter
The operating margin has soared by 99% YoY and by 49% from the previous quarter
IOVA's revenue has soared by 81% QoQ
Growth
What is Iovance Biotherapeutics's growth rate over time
Valuation
What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
1.52
P/S
6.25
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.69
The EPS has grown by 32% YoY and by 14% from the previous quarter
IOVA's price to book (P/B) is 69% less than its 5-year quarterly average of 4.5 and 65% less than its last 4 quarters average of 4.0
IOVA's equity is up by 22% year-on-year but it is down by 8% since the previous quarter
The price to sales (P/S) is 99% lower than the last 4 quarters average of 546.6
IOVA's revenue has soared by 81% QoQ
Efficiency
How efficient is Iovance Biotherapeutics business performance
The ROS has soared by 99% YoY and by 50% from the previous quarter
Iovance Biotherapeutics's ROIC has increased by 48% YoY and by 15% from the previous quarter
The return on assets has increased by 28% year-on-year and by 12% since the previous quarter
The ROE is up by 28% year-on-year and by 13% since the previous quarter
Dividends
What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IOVA.
Financial health
How did Iovance Biotherapeutics financials performed over time
The current ratio has increased by 34% YoY but it has decreased by 11% from the previous quarter
The total assets is up by 17% YoY but it is down by 8% from the previous quarter
Iovance Biotherapeutics's debt is 92% less than its equity
IOVA's debt to equity is down by 38% YoY and by 20% from the previous quarter
Iovance Biotherapeutics's debt has decreased by 26% from the previous quarter and by 23% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.